Sutro Biopharma (FRA:S090) Beneish M-Score: -0.94 (As of Jun. 27, 2026)


FRA:S090 Sutro Biopharma Inc FRA:S090
41 GF Score
Price €24.80
GF Value €10.36
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Sutro Biopharma Beneish M-Score?

Sutro Biopharma FRA:S090 -3.13% 41 Beneish M-Score is -0.94 as of Jun. 27, 2026. GuruFocus rates FRA:S090 with a GF Score™ of 41/100 and a GF Value™ of €10.36 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 831 Biotechnology companies, Sutro Biopharma ranks worse than 78.46% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -0.94 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Sutro Biopharma's Beneish M-Score or its related term are showing as below:

FRA:S090' s Beneish M-Score Range Over the Past 10 Years
Min: -4.77   Med: -1.94   Max: 8.78
Current: -0.94

During the past 10 years, the highest Beneish M-Score of Sutro Biopharma was 8.78. The lowest was -4.77. And the median was -1.94.


Sutro Biopharma Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Sutro Biopharma's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sutro Biopharma Beneish M-Score Chart

Sutro Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.78 -4.77 -0.04 -3.80 -1.79

Sutro Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.26 -1.00 -2.08 -1.79 -0.94

FRA:S090 vs CCCC, OCGN, FULC: Beneish M-Score Comparison

For the Biotechnology subindustry, Sutro Biopharma's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sutro Biopharma Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sutro Biopharma's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Sutro Biopharma's Beneish M-Score falls into.


FRA:S090
41GF Score
Sutro Biopharma Inc FRA:S090
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sutro Biopharma Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Sutro Biopharma for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.6183+0.528 * 1+0.404 * 2.7384+0.892 * 1.3922+0.115 * 0.7049
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.4815+4.679 * 0.127594-0.327 * 0.6959
=-1.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was €10.80 Mil.
Revenue was 12.562 + 9.947 + 8.258 + 55.267 = €86.03 Mil.
Gross Profit was 12.562 + 9.947 + 8.258 + 55.267 = €86.03 Mil.
Total Current Assets was €191.14 Mil.
Total Assets was €209.32 Mil.
Property, Plant and Equipment(Net PPE) was €16.50 Mil.
Depreciation, Depletion and Amortization(DDA) was €5.76 Mil.
Selling, General, & Admin. Expense(SGA) was €30.37 Mil.
Total Current Liabilities was €61.25 Mil.
Long-Term Debt & Capital Lease Obligation was €5.22 Mil.
Net Income was -33.289 + -39.935 + -48.442 + -9.97 = €-131.64 Mil.
Non Operating Income was -0.036 + -3.751 + -8.143 + -15.972 = €-27.90 Mil.
Cash Flow from Operations was -36.554 + -22.575 + -32.537 + -38.776 = €-130.44 Mil.
Total Receivables was €12.55 Mil.
Revenue was 16.094 + 14.143 + 7.677 + 23.881 = €61.80 Mil.
Gross Profit was 16.094 + 14.143 + 7.677 + 23.881 = €61.80 Mil.
Total Current Assets was €265.85 Mil.
Total Assets was €297.32 Mil.
Property, Plant and Equipment(Net PPE) was €30.60 Mil.
Depreciation, Depletion and Amortization(DDA) was €6.83 Mil.
Selling, General, & Admin. Expense(SGA) was €45.31 Mil.
Total Current Liabilities was €123.07 Mil.
Long-Term Debt & Capital Lease Obligation was €12.61 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(10.799 / 86.034) / (12.545 / 61.795)
=0.12552 / 0.20301
=0.6183

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(61.795 / 61.795) / (86.034 / 86.034)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (191.141 + 16.496) / 209.32) / (1 - (265.853 + 30.597) / 297.323)
=0.00804 / 0.002936
=2.7384

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=86.034 / 61.795
=1.3922

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(6.825 / (6.825 + 30.597)) / (5.758 / (5.758 + 16.496))
=0.182379 / 0.25874
=0.7049

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(30.371 / 86.034) / (45.307 / 61.795)
=0.353012 / 0.733182
=0.4815

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((5.218 + 61.252) / 209.32) / ((12.61 + 123.068) / 297.323)
=0.317552 / 0.456332
=0.6959

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-131.636 - -27.902 - -130.442) / 209.32
=0.127594

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Sutro Biopharma has a M-score of -1.03 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -0.94 mean?
Sutro Biopharma (FRA:S090) has a Beneish M-Score of -0.94 as of Jun. 27, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Sutro Biopharma and its competitors. According to the industry distribution chart, Sutro Biopharma ranks #652 out of 831 companies in the Biotechnology industry, placing it in the top 78.5%.
Is Sutro Biopharma's Beneish M-Score too high?
Sutro Biopharma's current Beneish M-Score is -0.94. Based on the distribution chart, Sutro Biopharma ranks #652 out of 831 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Sutro Biopharma has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sutro Biopharma's Beneish M-Score compare to CCCC and OCGN?
According to the Biotechnology industry distribution chart, Sutro Biopharma ranks #652 out of 831 companies for Beneish M-Score. This places Sutro Biopharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Sutro Biopharma and its competitors. Sutro Biopharma's current Beneish M-Score is -0.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sutro Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Sutro Biopharma (FRA:S090) is currently considered Significantly Overvalued. The stock's GF Value™ is €10.36, compared to a current price of €24.80 — trading 139.4% above its estimated fair value. The current Beneish M-Score is -0.94. Sutro Biopharma's overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Sutro Biopharma (FRA:S090), the current Beneish M-Score is -0.94 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sutro Biopharma (FRA:S090) Overvalued in 2026?

Based on GuruFocus' analysis, Sutro Biopharma stock appears to be overvalued. The current stock price of €24.80 is trading 139.4% above its estimated GF Value™ of €10.36. GuruFocus considers Sutro Biopharma to be Significantly Overvalued.

Key valuation signals for FRA:S090:

  • Beneish M-Score: -0.94
  • GF Value™: €10.36 vs. price of €24.80 (139.4% above fair value)
  • GF Score™: 41/100 with 4 warning signs

No single metric tells the full story. See the FRA:S090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sutro Biopharma Business Description

Other Exchanges STRO:USA
Address 111 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
41GF Score

Get the complete analysis for FRA:S090

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€24.80
Price
€10.36
GF Value